CNS demyelination [7] and “COVID fog” [13] following COVID-19 infection or vaccination has been reported in previous studies. However, the emergence of AD-like symptoms attributed to CNS demyelination is still an unexpected finding. The previous studies [7] [8] suggested that a considerable number of AD cases analogous to this one may had emerged after the peak of the COVID-19 pandemic. Therefore, we suggest that these analogous AD cases be categorized under a distinct subset within the long COVID syndromes, termed AD-like COVID syndromes. Given that plasma biomarker testing results align with those from Amyloid-PET and Tau-PET imaging, neither of these diagnostic methods can be used to reliably distinguish AD-like COVID syndromes from canonical AD. In this report, we characterized this unusual AD case by integrating data from various diagnostic methods, including PET, MRI imaging, genetic testing, plasma biomarker testing, etc, to aid in the identification of AD-like COVID syndromes in the future.